摘要
目的:比较哌拉西林/他唑巴坦单用与环丙沙星联合甲硝唑治疗复杂腹腔内感染的疗效。方法:回顾分析我院192例患者,均为术中留取标本,细菌培养显示有一种以上病原菌生长,并采用上述两种方案之一进行治疗。了解2组术中留取标本的耐药情况,并比较除耐药病例后的临床有效率等指标。结果:哌拉西林/他唑巴坦单用组与环丙沙星联合甲硝唑组分别有85例和107例,术中留取标本耐药率分别为5.9%(5/85)和21.5%(23/107)。除耐药病例后的临床有效率分别为92.5%(74/80)和77.4%(65/84),有显著性差异(P<0.05)。结论:不论是作为治疗复杂腹腔内感染的经验性药物,还是确定性药物,哌拉西林/他唑巴坦单用的效果均明显优于环丙沙星联合甲硝唑,应作为复杂腹腔内感染治疗的一线用药。
OBJECTIVE： To evaluate the efficacy of Piperacillin/Tazobactam versus Ciprofloxacin plus Metronidazole for complicated intraabdominal infection. METHODS： 192 patients whose bacterial culture test on intraoperative- resected sam- ples indicated growth of at least one pathogen were treated with Piperacillin/ Tazobactam versus Ciprofloxacin plus Metron- idazole for complicated intraabdominal infection. The drug resistance of the pathogens isolated form intraoperative - resected samples and the parameters including the clinical effective rate etc were compared between the two groups excluding the re- sistant cases. RESULTS： 85 case received Piperacillin/Tazobactam versus 107 cases received Ciprofloxacin plus Metronidazole, and the resistance rates of the pathogens isolated from the intraoperative- resected samples were 5.9% （5/85） and 21.5% （23/ 107）, respectively. The clinical effective rates in the two groups excluding the resistant cases were 92.5% （74/80） and 77.4% （65/ 84）, respectively, showing significant difference （P〈0.05） . CONCLUSION： Whether being used as empiric drug or confirmed drug for complicated intraabdominal infection, the efficacy of Piperacillin/ Tazobaetam is significantly superior to Ciprofloxacin plus Metronidazole, thus Piperacillin/ Tazobactam should be used as the first line therapy for complicated in- traabdominal infection.
出处
《中国药房》
CAS
CSCD
北大核心
2009年第17期1337-1339,共3页
China Pharmacy
关键词
复杂腹腔内感染
哌拉西林/他唑巴坦
环丙沙星
甲硝唑
Complicated intraabdominal infections
Piperacillin/Tazobactam
Ciprofloxacin
Metronidazole
